{"title":"[The development of innovative therapeutic drugs targeting hypoxia responses].","authors":"Kiyotsugu Yoshikawa, Hiroki Hagimoto, Eijiro Nakamura","doi":"10.1254/fpj.23090","DOIUrl":null,"url":null,"abstract":"<p><p>The 2019 Nobel Prize in Physiology or Medicine was awarded to Dr. William G. Kaelin Jr, Dr. Peter J. Ratcliffe, and Dr. Gregg L. Semenza for their elucidation of new physiological mechanisms \"How cells sense and adapt to oxygen availability\". Moreover, two different drugs, HIF-PH inhibitors and HIF-2 inhibitors were also developed based on the discovery. Interestingly, those three doctors have different backgrounds as a medical oncologist, a nephrologist, and a pediatrician, respectively. They have started the research based on their own unique perspectives and eventually merged as \"the elucidation of the response mechanism of living organisms to hypoxic environments\". In this review, we will explain how the translational research that has begun to solve unmet clinical needs successfully contributed to the development of innovative therapeutic drugs.</p>","PeriodicalId":12208,"journal":{"name":"Folia Pharmacologica Japonica","volume":"159 3","pages":"160-164"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Folia Pharmacologica Japonica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1254/fpj.23090","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The 2019 Nobel Prize in Physiology or Medicine was awarded to Dr. William G. Kaelin Jr, Dr. Peter J. Ratcliffe, and Dr. Gregg L. Semenza for their elucidation of new physiological mechanisms "How cells sense and adapt to oxygen availability". Moreover, two different drugs, HIF-PH inhibitors and HIF-2 inhibitors were also developed based on the discovery. Interestingly, those three doctors have different backgrounds as a medical oncologist, a nephrologist, and a pediatrician, respectively. They have started the research based on their own unique perspectives and eventually merged as "the elucidation of the response mechanism of living organisms to hypoxic environments". In this review, we will explain how the translational research that has begun to solve unmet clinical needs successfully contributed to the development of innovative therapeutic drugs.
2019 年诺贝尔生理学或医学奖授予了 William G. Kaelin Jr 博士、Peter J. Ratcliffe 博士和 Gregg L. Semenza 博士,以表彰他们阐明了 "细胞如何感知和适应氧气供应 "的新生理机制。此外,基于这一发现还开发出了两种不同的药物,即 HIF-PH 抑制剂和 HIF-2 抑制剂。有趣的是,这三位医生的背景各不相同,他们分别是肿瘤内科医生、肾脏内科医生和儿科医生。他们基于各自独特的视角开始研究,最终合并为 "阐明生物体对缺氧环境的反应机制"。在这篇综述中,我们将阐述为解决未满足的临床需求而开始的转化研究如何成功地促进了创新治疗药物的开发。